Krystal Biotech, Inc. (KRYS) stock
KRYSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 11/3052% above fair value
$315.34+16.79 (+5.62%)
Close on Nov 18, 2026Market cap $9.33BP/E 39.5Yield –
Krystal Biotech revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Krystal Biotech's revenue for the twelve months ending Jun 30, 2026 was $440.48M, up 22.6% year over year. For fiscal 2025 it was $389.13M, up 33.9% from the year before. The highest annual figure on record is $389.13M in fiscal 2025.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $389.13M | +33.9% |
| FY2024 | Dec 31, 2024 | $290.52M | +473.0% |
| FY2023 | Dec 31, 2023 | $50.70M | – |
| FY2022 | Dec 31, 2022 | $0 | – |
| FY2021 | Dec 31, 2021 | $0 | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $119.22M | +24.1% |
| Q1 FY2026 | Mar 31, 2026 | $116.36M | +31.9% |
| Q4 FY2025 | Dec 31, 2025 | $107.11M | +17.5% |
| Q3 FY2025 | Sep 30, 2025 | $97.80M | +16.6% |
| Q2 FY2025 | Jun 30, 2025 | $96.04M | +36.6% |
| Q1 FY2025 | Mar 31, 2025 | $88.18M | +94.9% |
| Q4 FY2024 | Dec 31, 2024 | $91.14M | +116.3% |
| Q3 FY2024 | Sep 30, 2024 | $83.84M | +879.9% |
| Q2 FY2024 | Jun 30, 2024 | $70.28M | – |
| Q1 FY2024 | Mar 31, 2024 | $45.25M | – |
| Q4 FY2023 | Dec 31, 2023 | $42.14M | – |
| Q3 FY2023 | Sep 30, 2023 | $8.56M | – |
| Q2 FY2023 | Jun 30, 2023 | $0 | – |
| Q1 FY2023 | Mar 31, 2023 | $0 | – |
| Q4 FY2022 | Dec 31, 2022 | $0 | – |
| Q3 FY2022 | Sep 30, 2022 | $0 | – |
See a number that looks wrong?